Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 6, 2015, Pages 650-658

  Tarkiainen, E K ^a   Holmberg, M T ^a   Tornio, A ^a   Neuvonen, M ^a   Neuvonen, P J ^a   Backman, J T ^a   Niemi, M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; CES1 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; ANTICOAGULATION; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYDROLYSIS; FEMALE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOGENETICS; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; GENETICS; GENOTYPE; HYDROLYSIS;

ADULT; CARBOXYLIC ESTER HYDROLASES; FEMALE; GENOTYPE; HUMANS; HYDROLYSIS; MALE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE;

EID: 84938941130     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.101     Document Type: Article

References (45)

1. Dansette, P.M., Rosi, J., Bertho, G. & Mansuy, D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem. Res. Toxicol. 25, 348-356 (2012).
2. Farid, N.A., Kurihara, A. & Wrighton, S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50, 126-142 (2010).
3. Mills, D.C. et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler. Thromb. 12, 430-436 (1992).
4. Tang, M. et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 319, 1467-1476 (2006).
5. Hagihara, K. et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos. 37, 2145-2152 (2009).
6. Caplain, H., Donat, F., Gaud, C. & Necciari, J. Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost. 25 (suppl. 2), 25-28 (1999).
7. Lins, R., Broekhuysen, J., Necciari, J. & Deroubaix, X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin. Thromb. Hemost. 25 (suppl. 2), 29-33 (1999).
8. Silvestro, L. et al. Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte backconversion. Anal. Bioanal. Chem. 401, 1023-1034 (2011).
9. Satoh, T. & Hosokawa, M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38, 257-288 (1998).
10. Satoh, T. & Hosokawa, M. Structure, function and regulation of carboxylesterases. Chem. Biol. Interact. 162, 195-211 (2006).
11. Markey, G.M. Carboxylesterase 1 (Ces1): from monocyte marker to major player. J. Clin. Pathol. 64, 107-109 (2011).
12. Laizure, S.C., Herring, V., Hu, Z., Witbrodt, K. & Parker, R.B. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33, 210-222 (2013).
13. Cuisset, T. et al. High post-treatment platelet reactivity identified lowresponders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 4, 542-549 (2006).
14. Gurbel, P.A., Bliden, K.P., Hiatt, B.L. & O'Connor, C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003).
15. Matetzky, S. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004).
16. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
17. Scott, S.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011).
18. Scott, S.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013).
19. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
20. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
21. Kim, K.A., Park, P.W., Hong, S.J. & Park, J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84, 236-242 (2008).
22. Marsh, S. et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84, 661-668 (2004).
23. Zhu, H.J. et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 82, 1241-1248 (2008).
24. Zhu, H.J. & Markowitz, J.S. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab. Dispos. 37, 264-267 (2009).
25. Tarkiainen, E.K., Backman, J.T., Neuvonen, M., Neuvonen, P.J., Schwab, M. & Niemi, M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin. Pharmacol. Ther. 92, 68-71 (2012).
26. Zhu, H.J., Wang, X., Gawronski, B.E., Brinda, B.J., Angiolillo, D.J. & Markowitz, J.S. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J. Pharmacol. Exp. Ther. 344, 665-672 (2013).
27. Lewis, J.P. et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet. Genomics 23, 1-8 (2013).
28. Li, Y., Tang, H.L., Hu, Y.F. & Xie, H.G. The gain-of-function variant allele CYP2C19∗17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J. Thromb. Haemost. 10, 199-206 (2012).
29. Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C. & Lithgow, J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19∗17. Br. J. Clin. Pharmacol. 69, 222-230 (2010).
30. Lewis, J.P. et al. The CYP2C19∗17 variant is not independently associated with clopidogrel response. J. Thromb. Haemost. 11, 1640-1646 (2013).
31. Tiroch, K.A. et al. Protective effect of the CYP2C19 ∗17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart J. 160, 506-512 (2010).
32. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
33. Zou, J.J., Chen, S.L., Fan, H.W., Tan, J., He, B.S. & Xie, H.G. CES1A - 816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention. J. Cardiovasc. Pharmacol. 63, 178-183 (2014).
34. Xie, C. et al. The effects of CES1A2 A(-816)C and CYP2C19 loss-offunction polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet. Genomics 24, 204-210 (2014).
35. Paré, G. et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127, 1404-1412 (2013).
36. Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. & Yokoi, T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab. Dispos. 38, 2173-2178 (2010).
37. Kristensen, K.E. et al. Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. Clin. Pharmacol. Ther. 96, 713-722 (2014).
38. Thomsen, R., Rasmussen, H.B., Linnet, K. & INDICES Consortium. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab. Dispos. 42, 126-133 (2014).
39. Yanjiao, X., Chengliang, Z., Xiping, L., Tao, W., Xiuhua, R. & Dong, L. Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro. Drug Metab. Pharmacokinet. 28, 468-474 (2013).
40. Delavenne, X., Basset, T., Zufferey, P., Malouk, N., Laporte, S. & Mismetti, P. Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. J. Sep. Sci. 33, 1968-1972 (2010).
41. Holmberg, M.T., Tornio, A., Neuvonen, M., Neuvonen, P.J., Backman, J.T. & Niemi, M. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin. Pharmacol. Ther. 95, 307-313 (2014).
42. Tornio, A. et al. Glucuronidation converts clopidogrel to a strong timedependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96, 498-507 (2014).
43. Malinin, A. et al. Monitoring platelet inhibition after clopidogrel with the Verify Now-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb. Res. 119, 277-284 (2007).
44. Lordkipanidzé, M., Pharand, C., Nguyen, T.A., Schampaert, E. & Diodati, J.G. Assessment of Verify Now P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther. Drug Monit. 30, 372-378 (2008).
45. Jeong, Y.H., Bliden, K.P., Antonino, M.J., Park, K.S., Tantry, U.S. & Gurbel, P.A. Usefulness of the Verify Now P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am. Heart J. 164, 35-42 (2012).